Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 10858440
Blanchard F, et al. (2000) Stimulation of leukemia inhibitory factor receptor degradation by extracellular signal-regulated kinase. J Biol Chem 275, 28793-801 10858440
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S1044-p - LIFR (human)
Modsite: WNLVsPDsPRsIDSN SwissProt Entrez-Gene
Orthologous residues
LIFR (human): S1044‑p, LIFR (mouse): S1039‑p, LIFR (rat): S1040‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site
Disease tissue studied:  liver cancer
Relevant cell lines - cell types - tissues:  H-35 (hepatic), HepG2 (hepatic)
Cellular systems studied:  cell lines
Species studied:  human, rat
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (rat) pharmacological inhibitor of upstream enzyme, electrophoretic mobility shift, modification site within consensus motif, pharmacological activator of upstream enzyme
KINASE ERK1 (rat) pharmacological inhibitor of upstream enzyme, electrophoretic mobility shift, modification site within consensus motif, pharmacological activator of upstream enzyme
Downstream Regulation
Effect of modification (function):  intracellular localization, protein degradation

T203-p - ERK1 (rat)
Modsite: HDHTGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  liver cancer
Relevant cell lines - cell types - tissues:  H-35 (hepatic)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LIF increase
U0126 LIF inhibit treatment-induced increase
IL-6 no change compared to control
insulin increase
oncostatin_M increase
U0126 oncostatin_M inhibit treatment-induced increase

Y205-p - ERK1 (rat)
Modsite: HTGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  liver cancer
Relevant cell lines - cell types - tissues:  H-35 (hepatic)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LIF increase
U0126 LIF inhibit treatment-induced increase
IL-6 no change compared to control
insulin increase
oncostatin_M increase
U0126 oncostatin_M inhibit treatment-induced increase

T183-p - ERK2 (rat)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  liver cancer
Relevant cell lines - cell types - tissues:  H-35 (hepatic)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LIF increase
U0126 LIF inhibit treatment-induced increase
IL-6 no change compared to control
insulin increase
oncostatin_M increase
U0126 oncostatin_M inhibit treatment-induced increase

Y185-p - ERK2 (rat)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  liver cancer
Relevant cell lines - cell types - tissues:  H-35 (hepatic)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LIF increase
U0126 LIF inhibit treatment-induced increase
IL-6 no change compared to control
insulin increase
oncostatin_M increase
U0126 oncostatin_M inhibit treatment-induced increase

Y705-p - STAT3 (rat)
Modsite: DPGSAAPyLKTKFIC SwissProt Entrez-Gene
Orthologous residues
STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 iso3 (human): Y705‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  liver cancer
Relevant cell lines - cell types - tissues:  H-35 (hepatic)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LIF increase
U0126 LIF no effect upon treatment-induced increase
IL-6 increase
insulin no change compared to control
oncostatin_M increase
U0126 oncostatin_M no effect upon treatment-induced increase